Análisis de ratios de rentabilidad
Datos trimestrales
Los ratios de rentabilidad miden la capacidad de la empresa para generar ventas rentables a partir de sus recursos (activos).
Ratios de rentabilidad (resumen)
Vertex Pharmaceuticals Inc., ratios de rentabilidad (datos trimestrales)
Basado en los informes: 10-Q (Fecha del informe: 2025-06-30), 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31).
Ratios de retorno de las ventas
Índices de retorno de la inversión
Ratio de margen de beneficio bruto
Vertex Pharmaceuticals Inc., ratio de margen de beneficio bruto, cálculo (datos trimestrales)
| 30 jun 2025 | 31 mar 2025 | 31 dic 2024 | 30 sept 2024 | 30 jun 2024 | 31 mar 2024 | 31 dic 2023 | 30 sept 2023 | 30 jun 2023 | 31 mar 2023 | 31 dic 2022 | 30 sept 2022 | 30 jun 2022 | 31 mar 2022 | 31 dic 2021 | 30 sept 2021 | 30 jun 2021 | 31 mar 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||
| Beneficio bruto | 2,557,200) | 2,407,200) | 2,488,600) | 2,379,300) | 2,273,700) | 2,348,000) | 2,149,700) | 2,164,800) | 2,184,600) | 2,107,900) | 2,019,400) | 2,044,900) | 1,934,400) | 1,851,700) | 1,825,174) | 1,747,652) | 1,565,398) | 1,531,976) | ||||||
| Ingresos | 2,964,700) | 2,770,200) | 2,912,000) | 2,771,900) | 2,645,600) | 2,690,600) | 2,517,700) | 2,483,500) | 2,493,200) | 2,374,800) | 2,302,700) | 2,334,300) | 2,196,200) | 2,097,500) | 2,072,561) | 1,984,164) | 1,793,370) | 1,724,305) | ||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||
| Ratio de margen de beneficio bruto1 | 86.11% | 86.03% | 86.11% | 86.12% | 86.45% | 86.86% | 87.21% | 87.80% | 87.92% | 88.04% | 87.90% | 88.00% | 88.13% | 87.95% | 88.06% | 87.94% | 87.89% | 88.06% | ||||||
| Referencia | ||||||||||||||||||||||||
| Ratio de margen de beneficio brutoCompetidores2 | ||||||||||||||||||||||||
| AbbVie Inc. | 70.93% | 70.69% | 69.99% | 67.21% | 62.75% | 62.28% | 62.42% | 65.76% | 68.91% | 69.43% | 70.00% | 69.62% | 70.48% | 69.53% | 68.96% | 67.72% | 65.62% | 64.82% | ||||||
| Amgen Inc. | 62.99% | 61.48% | 59.85% | 58.71% | 61.56% | 64.76% | 68.60% | 72.35% | 72.87% | 73.65% | 74.17% | 73.99% | 74.00% | 73.30% | 73.44% | 74.00% | 73.97% | 74.37% | ||||||
| Bristol-Myers Squibb Co. | 70.29% | 70.47% | 71.08% | 74.91% | 75.38% | 75.71% | 76.24% | 76.54% | 77.01% | 77.68% | 78.04% | 78.82% | 79.13% | 79.62% | 78.57% | 76.92% | 75.88% | 74.42% | ||||||
| Danaher Corp. | 59.66% | 59.74% | 59.50% | 59.37% | 59.27% | 58.39% | 58.74% | 58.77% | 59.17% | 60.22% | 60.21% | 60.65% | 60.77% | 60.77% | 60.95% | 60.44% | 59.24% | 57.60% | ||||||
| Eli Lilly & Co. | 82.64% | 81.70% | 81.31% | 80.91% | 80.75% | 80.16% | 79.25% | 78.67% | 77.77% | 77.67% | 76.77% | 75.61% | 75.98% | 74.40% | 74.18% | 74.85% | 74.27% | 75.88% | ||||||
| Gilead Sciences Inc. | 78.42% | 78.17% | 78.15% | 75.98% | 75.56% | 75.62% | 75.87% | 78.66% | 79.27% | 78.94% | 79.03% | 74.31% | 75.30% | 75.50% | 75.56% | 80.23% | 79.90% | 80.32% | ||||||
| Johnson & Johnson | 67.92% | 68.30% | 69.07% | 69.05% | 69.06% | 69.20% | 68.82% | 68.54% | 68.06% | 67.34% | 67.26% | 67.43% | 67.86% | 67.97% | 68.16% | 67.51% | 67.00% | 66.24% | ||||||
| Merck & Co. Inc. | 76.60% | 76.42% | 76.32% | 75.82% | 75.25% | 74.37% | 73.17% | 72.86% | 72.96% | 72.43% | 70.63% | 70.49% | 70.41% | 70.72% | 72.02% | 67.95% | 67.48% | 66.99% | ||||||
| Pfizer Inc. | 72.12% | 72.28% | 71.94% | 67.73% | 58.18% | 58.09% | 58.10% | 60.97% | 69.61% | 68.61% | 65.77% | 65.53% | 62.18% | 60.35% | 62.08% | 65.28% | 70.96% | 76.46% | ||||||
| Regeneron Pharmaceuticals Inc. | 85.57% | 85.79% | 86.13% | 86.12% | 86.16% | 86.32% | 86.16% | 85.96% | 86.42% | 86.96% | 87.18% | 85.39% | 84.97% | 84.65% | 84.83% | 86.65% | 86.85% | 86.84% | ||||||
| Thermo Fisher Scientific Inc. | 41.18% | 41.34% | 41.28% | 40.77% | 40.76% | 40.40% | 39.90% | 39.87% | 39.75% | 40.28% | 42.24% | 44.42% | 46.63% | 48.37% | 50.08% | 51.05% | 51.29% | 51.47% | ||||||
Basado en los informes: 10-Q (Fecha del informe: 2025-06-30), 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31).
1 Q2 2025 cálculo
Ratio de margen de beneficio bruto = 100
× (Beneficio brutoQ2 2025
+ Beneficio brutoQ1 2025
+ Beneficio brutoQ4 2024
+ Beneficio brutoQ3 2024)
÷ (IngresosQ2 2025
+ IngresosQ1 2025
+ IngresosQ4 2024
+ IngresosQ3 2024)
= 100 × (2,557,200 + 2,407,200 + 2,488,600 + 2,379,300)
÷ (2,964,700 + 2,770,200 + 2,912,000 + 2,771,900)
= 86.11%
2 Haga clic en el nombre del competidor para ver los cálculos.
Ratio de margen de beneficio operativo
Vertex Pharmaceuticals Inc., ratio de margen de beneficio operativo, cálculo (datos trimestrales)
| 30 jun 2025 | 31 mar 2025 | 31 dic 2024 | 30 sept 2024 | 30 jun 2024 | 31 mar 2024 | 31 dic 2023 | 30 sept 2023 | 30 jun 2023 | 31 mar 2023 | 31 dic 2022 | 30 sept 2022 | 30 jun 2022 | 31 mar 2022 | 31 dic 2021 | 30 sept 2021 | 30 jun 2021 | 31 mar 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||
| Ingresos (pérdidas) de operaciones | 1,151,100) | 630,100) | 1,026,000) | 1,116,300) | (3,514,700) | 1,139,500) | 988,500) | 1,038,100) | 1,026,400) | 779,000) | 1,033,500) | 1,126,700) | 1,106,300) | 1,040,900) | 877,723) | 1,054,512) | (37,961) | 887,826) | ||||||
| Ingresos | 2,964,700) | 2,770,200) | 2,912,000) | 2,771,900) | 2,645,600) | 2,690,600) | 2,517,700) | 2,483,500) | 2,493,200) | 2,374,800) | 2,302,700) | 2,334,300) | 2,196,200) | 2,097,500) | 2,072,561) | 1,984,164) | 1,793,370) | 1,724,305) | ||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||
| Ratio de margen de beneficio operativo1 | 34.36% | -6.69% | -2.11% | -2.54% | -3.37% | 41.16% | 38.83% | 40.16% | 41.72% | 43.93% | 48.23% | 47.72% | 48.85% | 36.93% | 36.73% | 37.17% | 33.93% | 47.14% | ||||||
| Referencia | ||||||||||||||||||||||||
| Ratio de margen de beneficio operativoCompetidores2 | ||||||||||||||||||||||||
| AbbVie Inc. | 18.80% | 17.56% | 16.22% | 24.89% | 22.31% | 23.50% | 23.49% | 27.32% | 31.03% | 28.49% | 31.21% | 30.59% | 30.33% | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | ||||||
| Amgen Inc. | 24.45% | 22.71% | 22.66% | 19.97% | 20.96% | 24.72% | 29.35% | 34.55% | 37.50% | 36.07% | 38.57% | 39.31% | 38.04% | 32.78% | 31.44% | 30.14% | 30.72% | 37.23% | ||||||
| Bristol-Myers Squibb Co. | 16.70% | 15.24% | -15.50% | -14.05% | -14.39% | -14.30% | 16.18% | 16.96% | 17.29% | 18.13% | 17.96% | 19.04% | 18.19% | 16.79% | 15.91% | -15.73% | -17.02% | -19.19% | ||||||
| Danaher Corp. | 18.39% | 20.26% | 20.37% | 20.11% | 21.22% | 21.05% | 21.77% | 23.83% | 25.06% | 27.02% | 27.61% | 27.35% | 25.44% | 25.23% | 25.35% | 24.63% | 25.04% | 22.30% | ||||||
| Eli Lilly & Co. | 32.37% | 28.74% | 28.64% | 24.81% | 23.28% | 20.80% | 18.92% | 18.42% | 24.17% | 22.45% | 24.97% | 24.65% | 25.50% | 25.94% | 22.45% | 23.17% | 21.81% | 22.06% | ||||||
| Gilead Sciences Inc. | 28.03% | 28.77% | 5.81% | 2.92% | 9.26% | 5.79% | 28.24% | 30.37% | 31.18% | 33.03% | 27.17% | 22.39% | 25.78% | 26.56% | 36.72% | 42.79% | 37.20% | 18.07% | ||||||
| Johnson & Johnson | 23.67% | 23.59% | 23.42% | 24.42% | 25.31% | 25.04% | 24.90% | 25.55% | 25.61% | 25.21% | 24.63% | 23.89% | 23.47% | 23.76% | 24.95% | 24.69% | 25.23% | 24.10% | ||||||
| Merck & Co. Inc. | 30.00% | 31.51% | 31.03% | 21.60% | 24.75% | 6.93% | 3.92% | 13.08% | 10.34% | 27.85% | 30.27% | 30.66% | 33.04% | 28.85% | 25.74% | 14.07% | 10.64% | 14.02% | ||||||
| Pfizer Inc. | 23.23% | 19.29% | 19.51% | 9.56% | -4.19% | -2.08% | 2.15% | 14.36% | 28.13% | 34.44% | 34.83% | 33.59% | 30.37% | 26.12% | 23.91% | 24.67% | 24.12% | 21.20% | ||||||
| Regeneron Pharmaceuticals Inc. | 27.02% | 27.20% | 28.10% | 28.69% | 28.95% | 29.40% | 30.85% | 32.23% | 34.20% | 35.79% | 38.93% | 45.45% | 48.19% | 55.08% | 55.67% | 55.19% | 53.94% | 43.37% | ||||||
| Thermo Fisher Scientific Inc. | 17.13% | 17.23% | 17.11% | 16.93% | 17.01% | 16.38% | 16.00% | 15.81% | 15.42% | 16.29% | 18.69% | 20.54% | 22.51% | 23.83% | 25.57% | 27.04% | 28.00% | 27.68% | ||||||
Basado en los informes: 10-Q (Fecha del informe: 2025-06-30), 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31).
1 Q2 2025 cálculo
Ratio de margen de beneficio operativo = 100
× (Ingresos (pérdidas) de operacionesQ2 2025
+ Ingresos (pérdidas) de operacionesQ1 2025
+ Ingresos (pérdidas) de operacionesQ4 2024
+ Ingresos (pérdidas) de operacionesQ3 2024)
÷ (IngresosQ2 2025
+ IngresosQ1 2025
+ IngresosQ4 2024
+ IngresosQ3 2024)
= 100 × (1,151,100 + 630,100 + 1,026,000 + 1,116,300)
÷ (2,964,700 + 2,770,200 + 2,912,000 + 2,771,900)
= 34.36%
2 Haga clic en el nombre del competidor para ver los cálculos.
Ratio de margen de beneficio neto
Vertex Pharmaceuticals Inc., ratio de margen de beneficio neto, cálculo (datos trimestrales)
| 30 jun 2025 | 31 mar 2025 | 31 dic 2024 | 30 sept 2024 | 30 jun 2024 | 31 mar 2024 | 31 dic 2023 | 30 sept 2023 | 30 jun 2023 | 31 mar 2023 | 31 dic 2022 | 30 sept 2022 | 30 jun 2022 | 31 mar 2022 | 31 dic 2021 | 30 sept 2021 | 30 jun 2021 | 31 mar 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||
| Utilidad (pérdida) neta | 1,032,900) | 646,300) | 913,000) | 1,045,400) | (3,593,600) | 1,099,600) | 968,800) | 1,035,300) | 915,700) | 699,800) | 818,900) | 930,500) | 810,500) | 762,100) | 770,110) | 851,928) | 66,924) | 653,138) | ||||||
| Ingresos | 2,964,700) | 2,770,200) | 2,912,000) | 2,771,900) | 2,645,600) | 2,690,600) | 2,517,700) | 2,483,500) | 2,493,200) | 2,374,800) | 2,302,700) | 2,334,300) | 2,196,200) | 2,097,500) | 2,072,561) | 1,984,164) | 1,793,370) | 1,724,305) | ||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||
| Ratio de margen de beneficio neto1 | 31.86% | -8.91% | -4.86% | -4.52% | -4.74% | 39.46% | 36.68% | 35.94% | 35.40% | 35.40% | 37.20% | 37.62% | 38.26% | 30.84% | 30.92% | 30.52% | 29.80% | 43.06% | ||||||
| Referencia | ||||||||||||||||||||||||
| Ratio de margen de beneficio netoCompetidores2 | ||||||||||||||||||||||||
| AbbVie Inc. | 6.45% | 7.31% | 7.59% | 9.22% | 9.71% | 11.02% | 8.95% | 11.81% | 15.50% | 13.37% | 20.39% | 23.19% | 22.04% | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | ||||||
| Amgen Inc. | 19.75% | 18.10% | 12.77% | 13.58% | 10.60% | 13.35% | 24.96% | 29.52% | 31.52% | 31.77% | 26.42% | 27.88% | 26.73% | 23.42% | 24.25% | 23.03% | 23.80% | 29.60% | ||||||
| Bristol-Myers Squibb Co. | 10.58% | 11.38% | -18.53% | -15.30% | -14.06% | -13.50% | 17.83% | 18.44% | 17.62% | 15.95% | 13.71% | 14.29% | 14.04% | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | ||||||
| Danaher Corp. | 14.21% | 15.81% | 16.33% | 16.39% | 17.83% | 18.54% | 19.94% | 22.89% | 22.80% | 23.32% | 22.91% | 21.65% | 20.61% | 21.32% | 21.84% | 20.97% | 21.00% | 19.17% | ||||||
| Eli Lilly & Co. | 25.91% | 22.66% | 23.51% | 20.48% | 18.86% | 17.08% | 15.36% | 15.55% | 22.01% | 20.54% | 21.88% | 20.63% | 19.58% | 20.90% | 19.71% | 21.52% | 22.71% | 23.91% | ||||||
| Gilead Sciences Inc. | 21.98% | 20.87% | 1.68% | 0.45% | 3.82% | 1.78% | 21.03% | 21.60% | 20.18% | 20.87% | 17.02% | 12.44% | 15.22% | 16.60% | 23.05% | 27.21% | 19.62% | 1.19% | ||||||
| Johnson & Johnson | 25.00% | 24.41% | 15.84% | 16.74% | 43.91% | 44.92% | 41.28% | 39.58% | 14.52% | 13.77% | 18.90% | 19.95% | 19.21% | 20.90% | 22.26% | 19.55% | 19.92% | 17.95% | ||||||
| Merck & Co. Inc. | 25.79% | 27.27% | 26.68% | 19.23% | 21.98% | 3.76% | 0.61% | 7.77% | 5.34% | 22.52% | 24.49% | 25.88% | 29.00% | 26.27% | 26.79% | 15.09% | 11.83% | 15.09% | ||||||
| Pfizer Inc. | 16.84% | 12.62% | 12.62% | 7.04% | -4.62% | -0.55% | 3.56% | 15.13% | 27.38% | 31.19% | 31.27% | 29.81% | 28.94% | 27.01% | 27.04% | 28.77% | 23.86% | 24.03% | ||||||
| Regeneron Pharmaceuticals Inc. | 31.37% | 31.94% | 31.07% | 33.61% | 32.04% | 29.45% | 30.14% | 30.47% | 33.93% | 33.81% | 35.64% | 39.17% | 39.97% | 48.06% | 50.25% | 51.65% | 50.11% | 43.53% | ||||||
| Thermo Fisher Scientific Inc. | 15.23% | 15.18% | 14.77% | 14.48% | 14.69% | 14.20% | 13.99% | 13.68% | 13.14% | 13.75% | 15.47% | 15.92% | 17.37% | 18.49% | 19.70% | 21.93% | 22.47% | 22.08% | ||||||
Basado en los informes: 10-Q (Fecha del informe: 2025-06-30), 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31).
1 Q2 2025 cálculo
Ratio de margen de beneficio neto = 100
× (Utilidad (pérdida) netaQ2 2025
+ Utilidad (pérdida) netaQ1 2025
+ Utilidad (pérdida) netaQ4 2024
+ Utilidad (pérdida) netaQ3 2024)
÷ (IngresosQ2 2025
+ IngresosQ1 2025
+ IngresosQ4 2024
+ IngresosQ3 2024)
= 100 × (1,032,900 + 646,300 + 913,000 + 1,045,400)
÷ (2,964,700 + 2,770,200 + 2,912,000 + 2,771,900)
= 31.86%
2 Haga clic en el nombre del competidor para ver los cálculos.
Ratio de rendimiento sobre el capital contable (ROE)
Vertex Pharmaceuticals Inc., ROE, cálculo (datos trimestrales)
| 30 jun 2025 | 31 mar 2025 | 31 dic 2024 | 30 sept 2024 | 30 jun 2024 | 31 mar 2024 | 31 dic 2023 | 30 sept 2023 | 30 jun 2023 | 31 mar 2023 | 31 dic 2022 | 30 sept 2022 | 30 jun 2022 | 31 mar 2022 | 31 dic 2021 | 30 sept 2021 | 30 jun 2021 | 31 mar 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||
| Utilidad (pérdida) neta | 1,032,900) | 646,300) | 913,000) | 1,045,400) | (3,593,600) | 1,099,600) | 968,800) | 1,035,300) | 915,700) | 699,800) | 818,900) | 930,500) | 810,500) | 762,100) | 770,110) | 851,928) | 66,924) | 653,138) | ||||||
| Patrimonio neto | 17,175,400) | 16,496,300) | 16,409,600) | 15,630,900) | 14,774,700) | 18,546,600) | 17,580,400) | 16,512,800) | 15,470,200) | 14,432,300) | 13,912,700) | 13,029,600) | 11,933,500) | 10,907,000) | 10,100,000) | 9,530,708) | 9,196,396) | 8,980,254) | ||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||
| ROE1 | 21.18% | -5.99% | -3.26% | -3.07% | -3.32% | 21.67% | 20.59% | 21.01% | 21.75% | 22.59% | 23.88% | 25.12% | 26.77% | 22.47% | 23.19% | 22.83% | 21.66% | 30.76% | ||||||
| Referencia | ||||||||||||||||||||||||
| ROECompetidores2 | ||||||||||||||||||||||||
| AbbVie Inc. | — | 295.42% | 128.66% | 84.91% | 78.77% | 74.85% | 46.94% | 53.86% | 67.50% | 57.14% | 68.60% | 83.83% | 86.24% | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | ||||||
| Amgen Inc. | 89.11% | 95.59% | 69.59% | 56.20% | 52.83% | 74.93% | 107.78% | 98.82% | 117.67% | 148.04% | 178.97% | 187.11% | 271.85% | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | ||||||
| Bristol-Myers Squibb Co. | 28.96% | 31.16% | -54.78% | -42.34% | -38.44% | -37.28% | 27.27% | 28.57% | 24.91% | 22.97% | 20.37% | 20.44% | 20.30% | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | ||||||
| Danaher Corp. | 6.52% | 7.40% | 7.87% | 7.59% | 8.42% | 8.24% | 8.91% | 11.29% | 12.30% | 13.47% | 14.39% | 14.40% | 13.63% | 13.93% | 14.24% | 13.54% | 13.12% | 11.76% | ||||||
| Eli Lilly & Co. | 75.52% | 70.45% | 74.62% | 58.78% | 54.14% | 47.91% | 48.65% | 44.46% | 58.73% | 50.82% | 58.64% | 59.91% | 66.61% | 65.69% | 62.16% | 76.99% | 94.20% | 88.31% | ||||||
| Gilead Sciences Inc. | 32.08% | 31.13% | 2.48% | 0.69% | 5.77% | 2.77% | 24.81% | 26.33% | 25.92% | 26.59% | 21.62% | 15.82% | 20.44% | 22.66% | 29.55% | 34.44% | 26.20% | 1.59% | ||||||
| Johnson & Johnson | 28.88% | 27.92% | 19.68% | 20.93% | 53.14% | 54.95% | 51.11% | 48.61% | 17.37% | 17.95% | 23.36% | 25.68% | 24.05% | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | ||||||
| Merck & Co. Inc. | 33.49% | 36.07% | 36.96% | 27.30% | 31.52% | 5.71% | 0.97% | 11.17% | 8.04% | 27.82% | 31.57% | 34.32% | 38.34% | 34.68% | 34.17% | 20.10% | 16.73% | 26.08% | ||||||
| Pfizer Inc. | 12.12% | 8.73% | 9.11% | 4.61% | -2.96% | -0.33% | 2.38% | 10.81% | 21.68% | 28.77% | 32.79% | 32.14% | 33.61% | 30.29% | 28.47% | 26.28% | 18.86% | 16.23% | ||||||
| Regeneron Pharmaceuticals Inc. | 14.89% | 15.31% | 15.03% | 15.87% | 15.32% | 14.29% | 15.22% | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | ||||||
| Thermo Fisher Scientific Inc. | 13.03% | 13.19% | 12.78% | 12.52% | 13.12% | 13.26% | 12.83% | 13.11% | 13.08% | 14.26% | 15.80% | 16.15% | 17.59% | 18.56% | 18.94% | 22.13% | 23.32% | 22.60% | ||||||
Basado en los informes: 10-Q (Fecha del informe: 2025-06-30), 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31).
1 Q2 2025 cálculo
ROE = 100
× (Utilidad (pérdida) netaQ2 2025
+ Utilidad (pérdida) netaQ1 2025
+ Utilidad (pérdida) netaQ4 2024
+ Utilidad (pérdida) netaQ3 2024)
÷ Patrimonio neto
= 100 × (1,032,900 + 646,300 + 913,000 + 1,045,400)
÷ 17,175,400 = 21.18%
2 Haga clic en el nombre del competidor para ver los cálculos.
Ratio de rentabilidad sobre activos (ROA)
Vertex Pharmaceuticals Inc., ROA, cálculo (datos trimestrales)
| 30 jun 2025 | 31 mar 2025 | 31 dic 2024 | 30 sept 2024 | 30 jun 2024 | 31 mar 2024 | 31 dic 2023 | 30 sept 2023 | 30 jun 2023 | 31 mar 2023 | 31 dic 2022 | 30 sept 2022 | 30 jun 2022 | 31 mar 2022 | 31 dic 2021 | 30 sept 2021 | 30 jun 2021 | 31 mar 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||
| Utilidad (pérdida) neta | 1,032,900) | 646,300) | 913,000) | 1,045,400) | (3,593,600) | 1,099,600) | 968,800) | 1,035,300) | 915,700) | 699,800) | 818,900) | 930,500) | 810,500) | 762,100) | 770,110) | 851,928) | 66,924) | 653,138) | ||||||
| Activos totales | 24,036,700) | 22,880,500) | 22,533,200) | 22,240,200) | 20,132,100) | 23,917,400) | 22,730,200) | 21,726,200) | 20,349,200) | 18,974,200) | 18,150,900) | 16,706,400) | 15,582,200) | 14,256,100) | 13,432,500) | 12,618,745) | 12,221,686) | 12,115,059) | ||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||
| ROA1 | 15.13% | -4.32% | -2.38% | -2.16% | -2.43% | 16.81% | 15.92% | 15.97% | 16.54% | 17.18% | 18.30% | 19.59% | 20.50% | 17.19% | 17.44% | 17.25% | 16.30% | 22.80% | ||||||
| Referencia | ||||||||||||||||||||||||
| ROACompetidores2 | ||||||||||||||||||||||||
| AbbVie Inc. | 2.74% | 3.08% | 3.17% | 3.57% | 3.76% | 4.03% | 3.61% | 4.78% | 6.42% | 5.64% | 8.53% | 9.49% | 8.83% | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | ||||||
| Amgen Inc. | 7.53% | 6.64% | 4.45% | 4.65% | 3.44% | 4.05% | 6.91% | 8.36% | 8.84% | 8.92% | 10.06% | 10.73% | 11.09% | 9.67% | 9.63% | 8.63% | 9.61% | 11.33% | ||||||
| Bristol-Myers Squibb Co. | 5.33% | 5.86% | -9.66% | -7.75% | -6.91% | -6.21% | 8.43% | 9.08% | 8.52% | 7.75% | 6.53% | 6.80% | 6.59% | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | ||||||
| Danaher Corp. | 4.18% | 4.76% | 5.03% | 4.83% | 5.35% | 5.28% | 5.64% | 6.74% | 7.49% | 8.15% | 8.55% | 8.35% | 7.76% | 7.74% | 7.73% | 7.13% | 7.19% | 6.30% | ||||||
| Eli Lilly & Co. | 13.67% | 12.42% | 13.45% | 11.07% | 10.22% | 9.60% | 8.19% | 8.61% | 11.85% | 10.70% | 12.62% | 12.71% | 12.09% | 13.06% | 11.44% | 12.39% | 12.70% | 13.01% | ||||||
| Gilead Sciences Inc. | 11.33% | 10.57% | 0.81% | 0.23% | 1.97% | 0.86% | 9.12% | 9.42% | 8.80% | 9.02% | 7.27% | 5.33% | 6.58% | 7.16% | 9.16% | 11.02% | 7.59% | 0.45% | ||||||
| Johnson & Johnson | 11.72% | 11.26% | 7.81% | 8.24% | 20.99% | 22.37% | 20.98% | 20.85% | 6.81% | 6.49% | 9.57% | 10.94% | 10.33% | 11.12% | 11.47% | 9.98% | 10.07% | 8.76% | ||||||
| Merck & Co. Inc. | 13.96% | 15.14% | 14.62% | 10.34% | 12.20% | 2.18% | 0.34% | 4.32% | 2.98% | 12.09% | 13.30% | 14.25% | 15.48% | 13.29% | 12.35% | 7.70% | 6.14% | 7.73% | ||||||
| Pfizer Inc. | 5.22% | 3.79% | 3.76% | 1.94% | -1.20% | -0.14% | 0.94% | 4.87% | 9.75% | 14.85% | 15.91% | 15.32% | 15.01% | 13.58% | 12.11% | 11.10% | 7.78% | 7.01% | ||||||
| Regeneron Pharmaceuticals Inc. | 11.67% | 11.98% | 11.69% | 12.43% | 11.98% | 11.22% | 11.95% | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | ||||||
| Thermo Fisher Scientific Inc. | 6.50% | 6.58% | 6.51% | 6.11% | 6.32% | 6.21% | 6.07% | 6.12% | 6.08% | 6.36% | 7.15% | 7.77% | 8.21% | 8.20% | 8.12% | 11.64% | 12.70% | 12.02% | ||||||
Basado en los informes: 10-Q (Fecha del informe: 2025-06-30), 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31).
1 Q2 2025 cálculo
ROA = 100
× (Utilidad (pérdida) netaQ2 2025
+ Utilidad (pérdida) netaQ1 2025
+ Utilidad (pérdida) netaQ4 2024
+ Utilidad (pérdida) netaQ3 2024)
÷ Activos totales
= 100 × (1,032,900 + 646,300 + 913,000 + 1,045,400)
÷ 24,036,700 = 15.13%
2 Haga clic en el nombre del competidor para ver los cálculos.